目的 利用数字化药品遴选模式促进医院药品供应目录合理化。方法 通过量化评价体系对院内供应药品及拟遴选药品逐项进行量化评价,赋予药品恰当分值,分析院内供应目录更新前后各项指标优化程度。结果 2020年第二季度药事管理与药物治疗学委员会更新目录中,经量化评价体系评分后,更新的药品目录中90%以上为评分最高分的品种,极少部分为分值处于低水平的药品,尚无最低分药品进入正式药品目录。统计2020年度药品目录更新前后各项指标分值高水平的药品占比,第一季度较第二季度、第二季度较第三季度均有统计学差异。结论 数字化药品遴选模式能一定程度上完善药品供应保障制度、规范药品目录,同时落实国家药品临床综合评价工作,推进省公立医疗机构用药目录遴选工作顺利开展。
Abstract
OBJECTIVE To promote the rationalization of the hospital drug selection list by using the digital drug selection mode. METHODS Through the quantitative evaluation system, the drugs supplied in the hospital and to be selected were quantitatively evaluated item by item, giving the drugs appropriate scores, and analyzing the optimization degree of various indicators before and after the update of the hospital supply directory. RESULTS In the updated list of the Pharmaceutical Management and Drug Treatment Committee in the second quarter of 2020, after the quantitative evaluation system rating, more than 90% of the updated drug list were the highest score, and a small part of them were drugs with low score, and no lowest score has yet entered the official drug list. Statistics were counted on the proportion of drugs with high levels of various indicators before and after the update of the drug directory in 2020, with statistical differences between the first quarter and the second quarter and between the second quarter and the third quarter. CONCULUSION The "digital" drug selection mode can improve the drug supply guarantee system and standardize the drug catalog to a certain extent, at the same time implement the national comprehensive evaluation work of drug use, and promote the smooth development of the selection work of drug directory in provincial public medical institutions.
关键词
数字化 /
药品遴选 /
目录优化 /
流程优化 /
药品目录
{{custom_keyword}} /
Key words
digital;drug selection /
directory optimization /
process optimization /
drug directory
{{custom_keyword}} /
中图分类号：
R95
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] TANG M, HAN S, WANG R, et al. Effects of canceling drug price addition policy on the change of drug structure in the public hospital in Beijing city. Chin Hosp Manag(中国医院管理), 2017, 37(10):4-6.
[2] ZHAO Z G, DONG Z J, LIU J P. A quick guidelien for drug evaluation and selection in Chinese medical institutions. Her Med(医药导报),2020,39(1):1457-1465.
[3] QIU B, LI X, YANG H T, et al. Application of HB-HTA in the assessment and selection of sulonyluteas. Chin Pharm J (中国药学杂志), 2021, 56(2):153-161.
[4] GUO Z D, CHI X YZ, MAO Y W, et al.The current status study on health technology assessment programs funded by National Natural Science Foundation of China. Chin Health Resour(中国卫生资源)2016, 5(19):440-443.
[5] LV L T, FU J L, LIN X, et al. Dilemma and outlet of hospital based health technology assessment in china Chin Hosp Manag(中国医院管理), 2019,39(2):7-10.
[6] WANG Z H, LI T, ZHAO Z N, et al. A rapid health technology assessment of nimotuzumab applicated in patients with advanced nasopharyngeal carcinoma. Chin Pharm J (中国药学杂志), 2021, 56(1):75-84.
[7] HU J J, CHEN X, GONG S W, et al. Analysis on the selection principle of rare drugs under the National Health Service Guarantee System in the United Kingdom, Canada and Australia. Med Soc(医学与社会), 2016, 29(1):36-40.
[8] SUN L H, SUN Q, LIU J Q. Successful experience of the selection of essential drugs in foreign country and its inspiration to China. J China Pharm(中国药房), 2010, 21(48):251-252.
[9] HUANG J, ZHANG Y G, LIU Y Q, et al. Briefly introduction of mini health technology assessment?. Chin J Evid-based Med (中国循证医学杂志), 2014, 14(8):901-904.
[10] JANKNEGT R. Triptans in the treatment of migraine:Drug selection by means of the SOJA method. Eur J Hosp Pharm,2007, 8(Suppl 1):S15-S30.
[11] WANG H Y, HE D, WANG X J, et al. Progress and recommendations for international and domestic application of health technology assessments. Chin J Health Policy(中国卫生政策研究), 2014, 7(8):19-23.
[12] SHAN X F, KONG L X, LONG R, et al. Optimization practice for the process of drug dispensing of inpatient pharmacy in our hospital. J China Pharm(中国药房), 2018, 19(24):3317-3321.
[13] ZHANG Z J. China Hospital Accreditation Practices(中国医院实践指南). Beijing: People's Military Medical Publishing House, 2013.
[14] HUANG J, LI X, WANG P, et al. Application and experience of quality management tools used in the reporting of ADR in our hospital. J China Pharm(中国药房), 2015, 26(8):85-88.
[15] ZHOU P, ZHAO X, AI D D, et al. Analysis on the mechanism of pharmaceuticaI procurement with target quantity in the New Era. China Health Econ(中国卫生经济), 2019, 38(5):78-80.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
白求恩医学科学研究基金项目资助(N089NH)
{{custom_fund}}
PDF(1611 KB)
